Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Avalyn Pharma Inc. (AVLN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34,28, with a market capitalisation of $1,55B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $24,15 to $40,17. This page covers its latest market performance, valuation, price trends and company information.
$1,55B | |
$34,31 | |
$40,17 | |
$24,15 | |
$34,28 | |
-- | |
312,38K | |
-- | |
$40,17 | |
$24,15 | |
-- | |
-- |
Avalyn Pharma Inc. (AVLN) is trading at $34,28 in pre-market trading as of 2026-09-16 08:03:00, up 0,01% ($0,00) from the previous close of $34,28
Pre-market trading shows how investors are pricing AVLN before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Avalyn Pharma Inc. (AVLN) moved from $37,39 to $34,28, representing a decline of 8,31% ($3,11).
The stock traded between $32,59 and $38,70 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 242,50 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 63,2%
AVLN is currently trading at $34,28, placing it 63,2% of the way from its 52-week low of $24,15 to its 52-week high of $40,17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Avalyn Pharma Inc. (AVLN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.